stockrowDesign Therapeutics, Inc.
DSGN Healthcare Biotechnology
- EPS
- −7.27%
- Free cash flow
- −7.00%
Quarter to September 2026, against a year earlier
Follow DSGN
Alert me
Design Therapeutics, Inc. (DSGN) EV/Sales
As of 6 November 2026, Design Therapeutics, Inc. (DSGN) trades at a EV/Sales of 1,919×. Over the past ten years it has ranged from −834× (August 2023) to 4,709× (August 2022); the current reading is higher than 73% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2020 | 2,740× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2020 | 2,740× | 0.00% |
| Sep 2020 | 2,740× | 0.00% |
| Jun 2020 | 2,740× | 0.00% |
| Mar 2020 | 2,740× | — |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| HELP Cybin Inc. compare | n/m |
| AVBP ArriVent BioPharma, Inc. compare | n/m |
| OBX Obsidian Therapeutics, Inc compare | n/m |
| IMMX Immix Biopharma, Inc. compare | n/m |
| KURA Kura Oncology, Inc. compare | 1.7× |
| GERN Geron Corporation compare | 2.6× |
| DBVT DBV Technologies S.A. compare | 211× |
| DSGN Design Therapeutics, Inc. | 1,919× |
| CADL Candel Therapeutics, Inc. compare | 3,940× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)